Background: Both metabolic syndrome (MetSyn) and the Renin Angiotensin Aldosterone System (RAAS) are predictors of adverse outcomes in stroke patients. This study aimed at evaluating the association between RAAS and MetSyn among ischaemic stroke subjects in a tertiary hospital of Ghana from September 2015 to June 2016. Methodology: The study purposively recruited 252 Ghanaians comprising 132 ischaemic stroke patients and 120 apparently healthy control subjects. The participants were subjected to measurements of plasma renin, serum aldosterone, lipid profile, anthropometries and blood pressure. Results: MetSyn prevalence among the stroke subjects compared to the controls were 50.0% vs 8.3% (NCEP/ATP III), 71.2% vs 9.2 (IDF) and 71.2% vs 6.7% (H_MS). Both renin and aldosterone were significantly (p < 0.05) higher in the ischaemic stroke subjects [(1.8 ± 0.1 vs 1.4 ± 0.1) pg/ml and (2.9 ± 0.2 vs 2.3 ± 0.2) pg/ml respectively]. Adjusting for age, gender, diabetes status and hypertension, third tertile (T 3 ) aldosterone (aOR = 2.7, p = 0.008), obesity (aOR = 11.7, p = 0.004) and high triglyceride (aOR = 5.3, p < 0.001) but not renin (aOR = 6.1, p = 0.742) were independently associated with increasing odds of metabolic syndrome. Moreover, there was a significant (p < 0.050) correlation between plasma renin and waist circumference How to cite this paper: Yeboah, F.A., Nkum, B., Amankwaa, B., Eghan Jr., B.A., Acheampong, E., Nsiah, P., Okyere, P., Owusu, L., Nsenba, E.B. and Anto, E.O. (WC) (r = 0.493) and high density lipoprotein (HDL) (r = −0.319). Significant (p < 0.050) correlations also existed between serum aldosterone and WC (r = 0.588), waist-to-height ratio (WHR) (r = 0.503), body mass index (BMI) (r = 0.691), HDL (r = −0.317), total cholesterol (r = 0.678) and triglyceride (r = 0.439). Conclusion: Aldosterone and not renin could play significant role in the pathophysiology of metabolic syndrome in ischaemic stroke. These findings underpin the observations that aldosterone is associated with several cardiovascular risk factors and may exacerbate metabolic defects in people with ischaemic stroke. Adequate aldosterone blockade could therefore mitigate the development and progression of metabolic syndrome in ischaemic stroke subjects.
Introduction
Stroke is an increasing public health concern globally and its victims are particularly susceptible to cardiometabolic complications including dyslipidaemia, diabetes and obesity [1] . Metabolic syndrome (MetSyn) on the other hand is a term coined for the clustering of cardiovascular risk factors including diabetes mellitus, hypertriglyceridaemia, central obesity, increased low density lipoprotein cholesterol (LDL-C) and decreased high density lipoprotein cholesterol (HDL-C) [1] . MetSyn has been shown to increase risk for stroke and other cardiovascular diseases [2] . According to [3] [4] , metSyn confers 5-fold risk for type 2 diabetes and 2 to 3 fold increased risk for coronary heart disease and future ischaemic stroke [3] [4] . Prevalence of MetSyn is estimated to range from <10% to as high as 84% depending on the region and underlying condition of study [5] . Previous studies have indicated high prevalence of metabolic syndrome particularly among ischaemic stroke subjects [1] [6] .
In a case-control study among Iranians, 62% stroke subjects compared to 34% normal controls had metabolic syndrome. Also, in a case-control study involving 100 Ghanaian subjects with various cardiovascular diseases (stroke, coronary heart disease, peripheral arterial disease or heart failure) the prevalence of MetSyn was 54% [7] .
Whereas the cause of metabolic syndrome is uncertain and is believed to be multifactorial, the renin angiotensin aldosterone system (RAAS) has been found to play a significant role in its pathophysiology [1] . RAAS has been linked to components of MetSyn including obesity, dyslipidaemia, hypertension and insulin resistance [2] [8] . Studies suggest that mineralocorticoid receptor (MR) antagonists could be important therapeutic agents in mitigating MetSyn and its complications [12] [13] .
However, data supporting the use of MR antagonists in ischaemic patients with the aim of preventing further metabolic defect is limited. There remains a paucity of data examining the relationship between the RAAS and the MetSyn in particularly ischaemic stroke. A better understanding of the association of RAAS and MetSyn may help in the management of ischaemic stroke subjects and thus minimize, if not entirely eradicate mortality from obesity, diabetes and hypertension [14] . Additionally, understanding the relationship between the RAAS and MetSyn in ischaemic strokes may help in the stratification and treatment of patients who may benefit substantially from RAAS blockade.
Materials and Method

Study Design and Setting
A case-control study which was carried out at the Medicine Department of Komfo Anokye Teaching Hospital (KATH) in the Ashanti Region of Ghana.
Komfo Anokye Teaching Hospital is the second largest tertiary hospital in Ghana with over a thousand bed capacity and is a major referral centre that provides health services to five other regions in Ghana. The study spanned through September 2015 to June 2016. However only two months were used to recruit the stroke cases due to its acute state.
Study Population and Subject Recruitment
A randomized sampling technique was used to recruit a total of 252 subjects (132 cases and 120 controls). The 132 sample size was based on the monthly incidence of stroke 44 (9.1%) at KATH [15] . The cases were admitted ischaemic stroke patients diagnosed with computerized tomographic scan and confirmed by a neurologist whereas apparently normal subjects without any history of CVD attending the hospital for medical check-ups served as controls. Patients with chronic kidney disease (protein-creatinine-ratio greater than 0.3 in women and 0.2 in men and/or eGFR < 60 mL/min/1.73 m 2 ) [16] , were exempted from the study.
Ethical Consideration
Ethical approval for the study (CHRPE/AP/377/15), was obtained from the 
Questionnaire
Structured questionnaire was administered to determine socio-demographics and identified risk factors of hypertension such as age, gender, and alcohol consumption and family history cardiovascular diseases.
Blood Pressure Measurement
Blood pressure (BP) measurements were done using the Omron M5-I digital fully automatic blood pressures monitor (Omron, Japan). After subjects had sat quietly for at least ten minutes, three measurements were taken at 5 minutes interval on the left arm in a seated position, with arm supported at heart level and feet flat on the floor. Hypertension was diagnosed when the mean of the second and third blood pressure (BP) measurements was equal to or above 140/90 mmHg [17] .
Measurement of Anthropometric Variables
Height to the nearest centimetre and weight to the nearest 0. All measurements were taken thrice and the means recorded.
Blood Sampling, Processing and Biochemical Assays
Fasting whole blood samples were drawn by venipuncture after 10 minutes of rest in a seated position in the morning between 6:30 and 9:30 AM. Blood was collected in EDTA tubes, maintained at 0˚C -4˚C during delivery to the laboratory, and rapidly frozen at −80˚C after centrifugation done at 500 g for 15 minutes. When ready to use, frozen blood samples were thawed at room temperature (25˚C). Plasma renin was measured as direct active renin (DAR; picograms per milliliter) by an immunoassay kit (Biobase Biotech (Jinan) Co. Ltd). The intra-assay and inter-assay coefficients of variation of the renin assay were <9%
and 15% respectively. The normal plasma renin range was given as 5.2 to 45.6 pg/ml in upright position [19] . Serum aldosterone was measured in pg/ml with immunoassay kit from Biobase Biotech (Jinan) Co. Ltd. The intra-assay and inter-assay coefficients of variation of the aldosterone assay were <9% and 15%
respectively. The reference interval was given as 65 pg/ml -450 pg/mL.
Fasting total cholesterol, high density lipoprotein (HDLc) and triglyceride 
Estimated Glomerular Filtration Rate and Diagnosis of Chronic Kidney Disease
Estimated glomerular filtration rate (eGFR) and was derived based on participants' serum creatinine, gender, age and race with the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [20] . CKD was defined by proteinuria (protein-creatinine-ratio greater than 0.3 in women and 0.2 in men)
and/or eGFR <60 mL/min/1.73 m 2 [16] .
Metabolic Syndrome Definition
Three metabolic syndrome definitions were defined as shown in Table 1 .
Data Analysis
Normality of all continuous variables was tested using the D'Agostino-Pearson omnibus normality test. All non-parametric variables were normalized by log transformation before analysis. Continuous variables were expressed as mean ± Standard deviation (SD) and median (inter-quartile range) where appropriate.
Categorical variables were expressed as frequency (n) and percentages (%). As- 
Results
The controls and stroke cases were age matched (p = 0.054) ( Table 5 . Moreover, serum aldosterone negatively and significantly correlated with HDL-cholesterol (r = −0.317, p < 0.05) in metabolic syndrome subjects but was insignificant in non-metabolic syndrome subjects (r = −0.429, p > 0.05). In addition, serum aldosterone was significantly associated with increasing triglyceride in the metabolic syndrome group (r = 0.439, p < 0.05) but not in the non-metabolic syndrome group (r = 0.225, p > 0.05).
Discussion
Metabolic syndrome (Metsyn) is known to increase the risk of adverse outcomes in stroke patients [24] [25]. Renin and aldosterone have been associated with the pathogenesis of obesity-related hypertension and weight loss has been shown to be complemented by reductions in plasma renin activity (PRA) and plasma aldosterone [26] . Albeit the role of the renin angiotensin aldosterone system in blood pressure regulation is well understood, its role in metabolic syndrome remains vague. In this study therefore, the relationships between the RAAS parameters and metabolic syndrome in some ischaemic stroke subjects were evaluated against data from apparently healthy cohorts within the same geographical boundary. (Table 2 and Table 3 ).
In this study, MetSyn prevalence in the ischaemic stroke subjects defined by IDF and HMS criteria are higher than in previous studies conducted among Chinese acute stroke subjects (51.35%), ischaemic stroke subjects in India (60%) and Iran (62%) [6] [10] [27] . The discrepancies could be due to the differences in proportions of co-morbidities among study subjects. For instance, Mi et al.
(2012) reported 87.5% hypertension prevalence in his subjects whereas 90.9% of the stroke subjects in this study were hypertensives. Sample size differences and inconsistencies in metabolic syndrome criteria could also have contributed to the differences in MetSyn prevalence.
The stroke subjects had significantly higher plasma renin, aldosterone and ARR compared to the control cohort (Table 2) suggesting that, the RAAS could have significant effect on cerebral circulation. In a review by [28] , angiotensin peptides and angiotensinergic neural pathways were found to be important in neural function. Though the distribution of angiotensin II receptor 1 (AT 1) coincides with some brain regions, neither renin nor angiotensin II and its related peptides nor renin pass readily from the blood into the brain interstitium [29] . Local intrinsic RAAS has therefore been proposed [30] . Moreover, high serum aldosterone was independently associated with metabolic syndromein this study (Table 4) . To the best of our knowledge, this is perhaps the first time RAAS and its role in MetSyn has been studied specifically in stroke subjects. The effect of aldosterone on MetSyn in other conditions has however been studied. Higher significant levels were found in MetSyn participants compared to non-MetSyn subjects among patients with obstructive sleep apnea hypopnea syndrome (OSAHS) [33] . Similarly, a cross-sectional study conducted in 356 participants from 69 families of African descent Seychelles found aldosterone to be independently associated with metabolic syndrome [34] .
Furthermore, Kidambi et al., (2007) found that plasma aldosterone levels and not PRA, were elevated in subjects with metabolic syndrome (P = 0.0002) in a study conducted in 182 hypertensive cases and 215 normotensive control Black Americans [26] . Besides increasing blood pressure, non-genomic effects of mineralocorticoid receptor (MR) activation by aldosterone has been found to also include activation of mitogen-activated protein (MAP) kinase and intercellular adhesion molecule (ICAM) 1 pathways which play key roles in atherosclerosis [35] . Aldosterone also increases the production of reactive oxygen species (ROS) through decreases in glucose-6-phosphate dehydrogenase activity and activation Open Access Library Journal , first tertile renin (<25.0 pg/ml), first tertile aldosterone (>504.0 pg/ml), desirable total cholesterol (<5.18 mmol/l), desirable triglyceride (<1.7 mmol/l), low HDL cholesterol (<1.0 mmol/l) and optimal LDL cholesterol (<2.59 mmol/l). of NAD (P) H oxidase [36] . Mineralocorticoid receptor antagonists used in combination with ACE inhibitors and or angiotensin II blockers (ARBs) have shown beneficial effects in diabetic nephropathy [37] .
MR antagonists may therefore have positive effects on various components of (Table 5) . Though the mechanism behind these correlations is not fully understood, aldosterone production has been shown to be stimulated by free fatty acids released from visceral adipose tissues [38] [39] . This is also consistent with the observation that drospirenone, an oral contraceptive with antimineralocorticoid properties, which is chemically related to spironolactone (a mineralocorticoid receptor blocker), significantly increased HDL cholesterol in young healthy women [40] . In this study, increasing plasma renin was not independently associated with metabolic syndrome (Table 4) . Contrary to this, among 29 volunteers with a range of risk factors studied, patients with more metabolic syndrome factor clustering including abdominal obesity and high blood pressure had significantly greater values for renin independent of dietary salt intake [41] . More recently, a prospective study involving 5301 African American adults, aged 21 -94 years showed that log-transformed plasma renin levels were associated with Metsyn and its components in fully adjusted models [42] .
In this study, plasma renin levels significantly correlated negatively (r = −0.319, p < 0.05) with HDL-cholesterol levels. Concordance with this study, multivariate logistic regression analysis in a cross-sectional study showed that high PRA was independently associated high HDL-C [43] . Another cross-sectional study in 985 subjects with metSyn and 515 without metSyn showed that renin levels increased and correlated inversely with HDL [44] . Conversely, in a [45] .
The effects of anti-hypertensive drugs could be the reason behind the contrary views expressed. We also witnessed a positive significant correlation between plasma renin and waist circumference (r = 0.493, p < 0.05). This is suggestive of renin playing key role in obesity and is in keeping with increased plasma angiotensinogen (a direct product of renin activity) in obese patients as compared with non-obese patients in a study by [46] . Moreover, an in vivo investigation of angiotensinogen (AGT) expression in adipose tissue and liver of Zucker rats during the onset of obesity showed adipocytes from obese rats displaying a significant increase in AGT content than in non-obese rats [47] .
Increased renin activity, a characteristic of an up regulated renin-angiotensinaldosterone system has been described in patients with visceral obesity which improves with weight loss [9] . This has been explained by many as a result of the presence of local renin-angiotensin-aldosterone system in the adipose tissue which may play a significant role in the pathophysiology of obesity and of obesity-related hypertension [11] [48] .
Whilst a case can be made about the potential role of both renin and aldosterone in the pathophysiology of metabolic syndrome among ischaemic stroke patients in this study, the use of case-control study design limits their absolute cause and effect relationship. Moreover, plasma renin was measured as a concentration other than the more standardized measurement of its activity that is plasma renin activity (PRA). Therefore, further studies which employ robust study design involving follow-ups and measurement of PRA instead of concentration are warranted to fully understand the mechanism behind the RAAS and metabolic syndrome.
Conclusion
This study has demonstrated a high prevalence of metabolic syndrome among ischaemic stroke patients at the Komfo Anokye Teaching Hospital. Raised blood aldosterone was shown to be significantly associated with metabolic syndrome in the stroke subjects. These findings underpin the observations that increased aldosterone levels may exacerbate metabolic defects in people with ischaemic stroke. Therefore, combination of standard treatments with available mineralocorticoid receptor antagonists including spironolactone and eplerenone in ischaemic strokes may halt further vascular deterioration and re-occurrence of stroke. Other potent risk factors identified were high blood pressure, obesity and triglyceridaemia. Further studies with larger sample size and robust study design involving follow ups are warranted to fully understand the role RAAS plays in cardio-metabolic syndrome in ischaemic strokes.
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